Literature DB >> 27747077

Anti-coagulation in pulmonary arterial hypertension: the real blood and guts.

Ioana R Preston1, Harrison W Farber2.   

Abstract

Entities:  

Year:  2016        PMID： 27747077      PMCID： PMC5059280          DOI： 10.21037/jtd.2016.08.48

Source DB:  PubMed          Journal:  J Thorac Dis        ISSN： 2072-1439            Impact factor:   2.895


× No keyword cloud information.
  7 in total

1.  Selexipag for the Treatment of Pulmonary Arterial Hypertension.

Authors:  Olivier Sitbon; Richard Channick; Kelly M Chin; Aline Frey; Sean Gaine; Nazzareno Galiè; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Irene M Lang; Ralph Preiss; Lewis J Rubin; Lilla Di Scala; Victor Tapson; Igor Adzerikho; Jinming Liu; Olga Moiseeva; Xiaofeng Zeng; Gérald Simonneau; Vallerie V McLaughlin
Journal:  N Engl J Med       Date:  2015-12-24       Impact factor: 91.245

Review 2.  Direct oral anticoagulants: new drugs and new concepts.

Authors:  Jerrold H Levy; Alex C Spyropoulos; Charles M Samama; James Douketis
Journal:  JACC Cardiovasc Interv       Date:  2014-12       Impact factor: 11.195

Review 3.  Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials.

Authors:  Nick van Es; Michiel Coppens; Sam Schulman; Saskia Middeldorp; Harry R Büller
Journal:  Blood       Date:  2014-06-24       Impact factor: 22.113

4.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Authors:  Nazzareno Galiè; Joan A Barberà; Adaani E Frost; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Vallerie V McLaughlin; Andrew J Peacock; Gérald Simonneau; Jean-Luc Vachiery; Ekkehard Grünig; Ronald J Oudiz; Anton Vonk-Noordegraaf; R James White; Christiana Blair; Hunter Gillies; Karen L Miller; Julia H N Harris; Jonathan Langley; Lewis J Rubin
Journal:  N Engl J Med       Date:  2015-08-27       Impact factor: 91.245

5.  Macitentan and morbidity and mortality in pulmonary arterial hypertension.

Authors:  Tomás Pulido; Igor Adzerikho; Richard N Channick; Marion Delcroix; Nazzareno Galiè; Hossein-Ardeschir Ghofrani; Pavel Jansa; Zhi-Cheng Jing; Franck-Olivier Le Brun; Sanjay Mehta; Camilla M Mittelholzer; Loïc Perchenet; B K S Sastry; Olivier Sitbon; Rogério Souza; Adam Torbicki; Xiaofeng Zeng; Lewis J Rubin; Gérald Simonneau
Journal:  N Engl J Med       Date:  2013-08-29       Impact factor: 91.245

6.  Anticoagulation and survival in pulmonary arterial hypertension: results from the Comparative, Prospective Registry of Newly Initiated Therapies for Pulmonary Hypertension (COMPERA).

Authors:  Karen M Olsson; Marion Delcroix; H Ardeschir Ghofrani; Henning Tiede; Doerte Huscher; Rudolf Speich; Ekkehard Grünig; Gerd Staehler; Stephan Rosenkranz; Michael Halank; Matthias Held; Tobias J Lange; Juergen Behr; Hans Klose; Martin Claussen; Ralf Ewert; Christian F Opitz; C Dario Vizza; Laura Scelsi; Anton Vonk-Noordegraaf; Harald Kaemmerer; J Simon R Gibbs; Gerry Coghlan; Joanna Pepke-Zaba; Uwe Schulz; Matthias Gorenflo; David Pittrow; Marius M Hoeper
Journal:  Circulation       Date:  2013-09-30       Impact factor: 29.690

7.  Effect of Warfarin Treatment on Survival of Patients With Pulmonary Arterial Hypertension (PAH) in the Registry to Evaluate Early and Long-Term PAH Disease Management (REVEAL).

Authors:  Ioana R Preston; Kari E Roberts; Dave P Miller; Ginny P Sen; Mona Selej; Wade W Benton; Nicholas S Hill; Harrison W Farber
Journal:  Circulation       Date:  2015-10-28       Impact factor: 29.690
  7 in total
  1 in total

Review 1.  Chronic thromboembolic pulmonary hypertension: a review.

Authors:  Cheryl Zhiya Chong; Edgar Lik Wui Tay; Ching Hui Sia; Kian Keong Poh
Journal:  Singapore Med J       Date:  2021-07       Impact factor: 1.858
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.